Skip to main navigation

For Patients

|

For Physicians

Header Links

Solutions
Investors
Meet the Team
News
Careers
Contact Us
For Patients
For Physicians

News Releases

Events and Presentations

Press Coverage
News Releases
Investor Calendar

Keyword Search

Year

12/18/24

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

12/16/24

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

12/10/24

Neuronetics and Greenbrook TMS Announce Closing of Transaction

11/20/24

Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference

11/12/24

CORRECTION—Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results

11/12/24

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

11/12/24

Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results

10/29/24

Neuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call

10/14/24

NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression

09/25/24

Health Care Service Corporation Adds First-Line TMS Coverage for Adolescents

09/19/24

Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults

09/16/24

NeuroStar® Releases Software Upgrades to Elevate Patient Care

09/03/24

NeuroStar Honors Suicide Prevention Month With Milestone Achievement and Powerful Stories

08/20/24

NeuroStar® Marks Two Years of Transformative Impact with NeuroStar University

08/12/24

Neuronetics and Greenbrook TMS Announce Definitive Agreement to Merge

08/12/24

Neuronetics Reports Record Second Quarter 2024 Financial and Operating Results

08/05/24

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

08/01/24

NeuroStar Partners With This Is My Brave to Recognize Teen Mental Health Month

07/31/24

Neuronetics to Present at the Canaccord Genuity 44th Annual Growth Conference

07/30/24

Neuronetics Announces the Closing of up to $90 Million Senior Secured Credit Facility with Perceptive Advisors

07/29/24

Neuronetics to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call

07/22/24

Aetna Policy Update Expands TMS Availability for Adolescents With Depression

07/11/24

California Medicaid Adds TMS Access for 14.8 Million Adolescents and Adults

07/10/24

BlueCross BlueShield MI and Cambia Health Solutions Expand TMS Access for Depressed Adolescents

07/01/24

NeuroStar® Launches Better Me Provider Program Nationwide

06/13/24

NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting

05/23/24

Neuronetics to Present at the William Blair 44th Annual Growth Stock Conference

05/15/24

Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents

05/07/24

Neuronetics Reports Record First Quarter 2024 Financial and Operating Results

05/03/24

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

05/01/24

NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month

04/23/24

Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call

04/10/24

New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital

03/27/24

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03/25/24

NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression

03/07/24

Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network

03/05/24

Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results

02/20/24

Neuronetics to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call

02/12/24

Neuronetics Launches Latest Evolution in its TrakStar® Patient Data Management System

02/06/24

NeuroStar TMS Patient Access Expands Through Lucet Health Policy Update

01/08/24

Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results

Shareholder Tools

View printer-friendly version
RSS Feeds
E-mail Alerts
View contacts

*Free consultations are determined by providers and may not be guaranteed.

**Outcomes Registry data was published by Sackeim HA, et al. J Affective Disorders, 2020, 277(12):65-74. The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score <=3 and “complete remission” was defined as a CGI-S score <=2 at the end of treatment.

***Patients received more than one course of treatment and were treated with standard of care. Standard of care also included medications. CGI-S represents the scale used to define response and remission.

Indication

The NeuroStar Advanced Therapy System is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode.

The NeuroStar Advanced Therapy system is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).

NeuroStar Advanced Therapy is only available by prescription. A doctor can help decide if NeuroStar Advanced Therapy is right for you. Patients’ results may vary.

Important Safety Information

The most common side effect is pain or discomfort at or near the treatment site. These events are transient; they occur during the TMS treatment course and do not occur for most patients after the first week of treatment. There is a rare risk of seizure associated with the use of TMS therapy (<0.1% per patient).

NeuroStar Advanced Therapy should not be used with patients who have non-removable conductive metal in or near the head. NeuroStar Advanced Therapy has not been studied in patients who have not received prior antidepressant treatment.

Safety and Prescribing Information »

Social Links

Our Commitment

Neuronetics is committed to compliance with state and federal laws regarding interaction with healthcare providers.

Commitment to Compliance »

To find out more about NeuroStar^® Advanced Therapy or where treatment is available near you, please provide your contact information and a Neuronetics customer service representative will contact you. The information you provide to us is subject to the Neuronetics Privacy Policy.

General Contact Information »

Customer Service Center: 877-600-7555

Copyright @ 2024 Neuronetics Inc. All Rights Reserved.
Website and materials within are for U.S. use only.